Clinical trials: Hyperkalaemia, active
Acute Kidney Injury, Renal Insufficiency,Chronic
Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial
This study is testing whether finerenone, when compared to placebo, is a tolerable and safe intervention when administered in patients with acute kidney injury (AKI).
- Conditions
- Acute Kidney Injury, Renal Insufficiency,Chronic, Kidney Diseases
- Trial name
- FiPAKI (NCT07775482)
- Testing
- Finerenone (BAY94-8862 ) 10 mg
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Jean-Maxime Côté
Hyperkalaemia
AI-Enabled ECG Stratification and Timing of Potassium-Lowering Therapy in Patients With Hyperkalemia: A Target Trial Emulation Study
Hyperkalemia is a common and potentially life-threatening electrolyte disorder, yet there is limited evidence guiding the optimal timing of potassium-lowering therapy in routine clinical practice.
- Trial name
- AIDE-K (NCT07307729)
- Testing
- Timely treatment, Delayed treatment
- Volunteers
- 5,000 people
- Sponsor
- National Defense Medical Center, Taiwan
Chronic Kidney Disease, Type 2 Diabetes
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
The goal of this clinical trial is to learn if starting four kidney disease medicines quickly and together (a rapid treatment approach) is safe and works well in people with type 2 diabetes and chronic kidney disease.
- Trial name
- RAPID-CKD (NCT07547878)
- Testing
- Finerenone, Semaglutide, Lotensin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Baylor Research Institute
Hyperkalemia
Lower vs. Standard Insulin-Dextrose Doses for Treating Mild to Moderate Hyperkalemia in the Emergency Department
This clinical trial aims to evaluate the safety and efficacy of a lower dose insulin compared to the conventional dose for treating mild to moderate hyperkalemia, a condition characterized by elevated serum potassium levels below…
- Trial name
- IDK+ (NCT06724991)
- Testing
- Lower Dose Therapy, Conventional Dose Therapy
- Where
- Malaysia
- Volunteers
- 50 people
- Sponsor
- University of Malaya
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
The goal of this observational pilot study is to evaluate the investigational AK+ Guard™ software as a medical device (SaMD) for detection of moderate to severe hyperkalemia (serum potassium (K+) ≥ 6.5 mmol/L) in adults with…
- Trial name
- NCT07210021
- Testing
- AK+ Guard™ ECG Application
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- AccurKardia, Inc.
Dysequilibrium Syndrome, ESRD
Adding Urea to the Final Dialysis Fluid
At times patients with advanced renal failure present with severe hyperkalemia or acidosis and very high serum blood urea nitrogen (BUN) concentrations.
- Conditions
- Dysequilibrium Syndrome, ESRD, Hyperkalemia, Metabolic Acidosis
- Trial name
- Urea dialysate (NCT06366230)
- Testing
- Urea in the dialysate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Hyperkalemia, Diminished Renal Excretion
Evidence for Potassium Restriction in Hemodialysis
EvoKe-HD is a pilot randomized controlled trial to assess the feasibility and potential for efficacy of a novel dietary approach to hyperkalemia.
- Trial name
- EvoKe-HD (NCT06120608)
- Testing
- Novel dietary approach focused on restricting the intake of highly bioavailable potassium, Traditional approach
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Chronic Kidney Disease on Hemodialysis, Hypokalemia
the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients
The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important…
- Conditions
- Chronic Kidney Disease on Hemodialysis, Hypokalemia, Hyperkalemia, Myocardial Injury
- Trial name
- NCT06736184
- Testing
- Sodium Zirconium Cyclosilicate (SZC)
- Volunteers
- 100 people
- Sponsor
- Qianfoshan Hospital
Heart Failure, Chronic Kidney Diseases
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and…
- Trial name
- SENEKA (NCT06578078)
- Testing
- Sodium Zirconium Cyclosilicate, Standard of care treatment (RAASi therapy)
- Where
- 6 sites in Spain
- Volunteers
- 94 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Chronic Kidney Diseases
Keeping RAASi Treatment With Optimal Potassium Control
Phase III, multicenter, randomized, open-label, parallel-group, non-inferiority, phase III clinical trial comparing CSZ (Lokelma) vs. iSRAA discontinuation/reduction and/or ARM (standard treatment).
- Trial name
- KEEP-ON (NCT06578533)
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 5 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Hyperkalemia, Chronic Kidney Disease(CKD)
Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community
The goal of this observational study is to investigate the prevalence and risk factors of hyperkalemia in community-based non-dialysis chronic kidney disease (CKD) patients. The main questions it aims to answer are: 1.
- Trial name
- NCT06940414
- Testing
- No Intervention
- Where
- China
- Volunteers
- 1,890 people
- Sponsor
- Xiujuan Zang
Chronic Kidney Disease (Stages 3b-5)
Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
The clinical trial will be conducted in a real-world outpatients setting with the goal of learning if monitoring serum potassium frequently among patients with moderate-to-advanced stages of chronic kidney disease leading to…
- Trial name
- POCKET (NCT06901960)
- Testing
- A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (<5 mmol/L, 5 - <5.5 mmol/L, 5.5 - <6.0 mmol/L and ≥ 6.0 mmol/L)
- Where
- 3 sites in China
- Volunteers
- 1,066 people
- Sponsor
- Peking University First Hospital
Heart Failure, Hyperkalemia
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
Mineralocorticoid receptor antagonists (MRA) is one of cornerstones in the treatment of heart failure with reduced ejection fraction (HFrEF). However, MRA has been extremely under-used globally.
- Trial name
- OPRA-HF (NCT04789239)
- Testing
- Sodium zirconium cyclosilicate
- Where
- 2 sites in Sweden
- Volunteers
- 110 people
- Sponsor
- Michael Fu
Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User
Targeted Potassium Levels for Prevention of ICD Therapy
This study evaluates whether a rigorously controlled high-normal level of serum-potassium (4.5-5.0 mEq/L) using dietary recommendations, potassium supplements and mineralocorticoid receptor antagonists will results in a lower…
- Conditions
- Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User, Hypokalemia, Hyperkalemia
- Trial name
- NCT03833089
- Testing
- Targeted serum potassium level
- Where
- 3 sites in Denmark
- Volunteers
- 1,200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4
Patiromer and Diet/hrQoL in Chronic Dialysis
This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or…
- Conditions
- Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention
- Trial name
- PRINCE (NCT06858280)
- Testing
- Patiromer 8400 MG [Veltassa]
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Hyperkalemia
A Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia
This clinical trial is an open-label, consisting of 2 phases, corrective phase (CP) and a maintenance phase (MP). The corrective phase aims to correct hyperkalemia within 24 to 72 hours, the maintenance phase aims to maintain the…
- Trial name
- NCT07881965
- Testing
- WS016
- Where
- 50 sites in China
- Volunteers
- 300 people
- Sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.
Heart Failure, Diabetic Kidney Disease
Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
This study evaluates the safety of finerenone compared with alternate-day spironolactone in patients with heart failure and diabetic kidney disease at increased risk of hyperkalemia.
- Conditions
- Heart Failure, Diabetic Kidney Disease, Hyperkalemia
- Trial name
- SAFE-K (NCT07523867)
- Testing
- Finerenone, Spironolactone (drug)
- Volunteers
- 60 people
- Sponsor
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Chronic Kidney Diseases, Hyperkalemia
Potassium Correction for RAAS Optimization in Chronic Kidney Disease
The goal of this placebo-controlled, double-blinded cross-over trial is to test whether patiromer, compared with placebo, better enables up-titration of RAAS-blocker treatment in patients with chronic kidney disease stage 3b/4.
- Conditions
- Chronic Kidney Diseases, Hyperkalemia, Hypertension
- Trial name
- PROMISE (NCT06256991)
- Testing
- Patiromer 8400 MG [Veltassa]
- Where
- Netherlands
- Volunteers
- 44 people
- Sponsor
- University Medical Center Groningen
Hyperkalemia
Hyperkalemia Quality Improvement Program (HK-QIP) Study
This is a prospective, multi-center, single-arm study to evaluate the impact of implementation of guideline determined medical therapy (GDMT) for quality control improvement in non-dialysis chronic kidney disease (CKD-ND)…
- Trial name
- HK-QIP (NCT06884267)
- Testing
- standard hyperkalemia management implementation
- Where
- 49 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca